EU remote
Associate Director, Market Access AMNOG, Germany
About this role
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients. The Opportunity: The Associate Director, Market Access, Germany is responsible for defining and executing the market access strategy to ensure timely, sustainable patient access to innovative oncology therapies. Working closely with the Senior Director, Market Access, in Germany, this role helps to shape business strategies, drives value demonstration, and leads engagement with key external stakeholders including payers, HTA bodies, and health authorities.
The incumbent will partner with regional and global commercial, HEOR, and medical affairs teams to deliver launch activities by providing access insights, developing evidence-based HTA, Pricing & Reimbursment dossiers and tools, engaging with market access and public affairs stakeholders as well as participating in pricing strategy activities, and drive the activities to deliver access results supporting the overall success of the product launches.
Responsibilities: Market Access & Reimbursement: Develop and implement strategies to support access and pricing decisions for oncology products within the German healthcare system. HTA & Pricing Filings: Lead preparation and submission of value dossiers, benefit assessments (e.g., AMNOG/G-BA) and pricing negotiations with statutory health insurance decision makers (e.g., GKV-SV). Value Communication: Translate clinical and economic evidence into compelling value communications tailored for German payers.